JW Pharmaceutical has announced it has secured exclusive domestic rights for **bofanglutide**, a pioneering next-generation **GLP-1 receptor agonist**, through a strategic licensing agreement with China’s Gan & Lee Pharmaceuticals. This significant deal positions JW Pharmaceutical to introduce an innovative treatment option to the South Korean market, targeting multiple metabolic conditions.
Under the terms of this exclusive partnership, JW Pharmaceutical will spearhead the complete development, regulatory approval processes, and commercialization of bofanglutide across South Korea. Gan & Lee Pharmaceuticals will provide essential clinical data and documentation to facilitate investigational new drug (IND) and subsequent product approvals in the region.
The robust licensing agreement is valued at a significant $81.1 million, comprising a $5 million upfront payment and up to $76.1 million in milestone payments. These milestones are linked to the successful regulatory approvals for bofanglutide across four critical indications: **type 2 diabetes**, **obesity management**, **obstructive sleep apnea**, and **metabolic dysfunction-associated steatohepatitis (MASH)**. Additionally, separate royalties will be disbursed based on product sales, reflecting the long-term potential of this advanced GLP-1 therapy.
Bofanglutide has already demonstrated compelling efficacy in its clinical development. A pivotal Phase 2b study revealed an impressive average weight loss of 17.3 percent in patients over 30 weeks with a convenient biweekly dosing regimen. This significant outcome firmly positions bofanglutide as a leading contender for a **next-generation obesity treatment** with substantial market potential.
Building on this promising data, JW Pharmaceutical is set to initiate domestic Phase 3 clinical trials for both obesity and type 2 diabetes indications in South Korea during the second half of this year, fast-tracking its path to market for these critical health areas.
This strategic partnership aligns with the escalating global demand for advanced GLP-1 therapies. Projections from Grand View Research indicate substantial growth in the Asia-Pacific GLP-1 market, forecasting a surge from $5.5 billion in 2025 to nearly $17 billion by 2033, highlighting the immense commercial opportunity for bofanglutide in the region.
“Our commitment is to accelerate the commercialization of bofanglutide, ensuring we can provide innovative and much-needed treatment options for patients dealing with these challenging metabolic conditions,” stated Shin Young-sup, CEO of JW Pharmaceutical.
A spokesperson for Gan & Lee Pharmaceuticals affirmed that this strategic collaboration will significantly bolster bofanglutide’s development trajectory and market expansion efforts within South Korea.
stlee0329
